ORMP Stock Overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Oramed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.60 |
| 52 Week High | US$19.00 |
| 52 Week Low | US$6.61 |
| Beta | 1.82 |
| 1 Month Change | -17.15% |
| 3 Month Change | 6.49% |
| 1 Year Change | 1.13% |
| 3 Year Change | -72.15% |
| 5 Year Change | -37.04% |
| Change since IPO | -71.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORMP | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | -14.0% | -2.9% | -0.7% |
| 1Y | 1.1% | -17.3% | 10.4% |
Return vs Industry: ORMP exceeded the IL Pharmaceuticals industry which returned -17.7% over the past year.
Return vs Market: ORMP underperformed the IL Market which returned 8.3% over the past year.
Price Volatility
| ORMP volatility | |
|---|---|
| ORMP Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.4% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: ORMP's share price has been volatile over the past 3 months.
Volatility Over Time: ORMP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Nadav Kidron | www.oramed.com |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. Fundamentals Summary
| ORMP fundamental statistics | |
|---|---|
| Market cap | ₪358.32m |
| Earnings (TTM) | ₪20.97m |
| Revenue (TTM) | ₪5.09m |
16.1x
P/E Ratio66.5x
P/S RatioIs ORMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORMP income statement (TTM) | |
|---|---|
| Revenue | US$1.34m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.34m |
| Other Expenses | -US$4.18m |
| Earnings | US$5.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 100.00% |
| Net Profit Margin | 412.31% |
| Debt/Equity Ratio | 31.3% |
How did ORMP perform over the long term?
See historical performance and comparison